Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 2 of 5 for:    cellphire

Thrombosomes® in Bleeding Thrombocytopenic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03394755
Recruitment Status : Unknown
Verified January 2019 by Cellphire Therapeutics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : January 9, 2018
Last Update Posted : July 11, 2019
Department of Health and Human Services
Information provided by (Responsible Party):
Cellphire Therapeutics, Inc.

Brief Summary:
This study evaluates in a dose-escalation manner, the safety, and preliminary impact on bleeding, and the preliminary effect on coagulation measures of increasing doses of allogeneic Thrombosomes in thrombocytopenic patients.

Condition or disease Intervention/treatment Phase
Thrombocytopenia Hematologic Diseases Bone Marrow Aplasia Biological: Thrombosomes Phase 1

Detailed Description:
The objectives of this trial, conducted in thrombocytopenic patients with modified World Health Organization (WHO) Grade 1* or 2 bleeding, assessing the safety of infusing increasing doses of allogeneic Thrombosomes in WHO bleeding and measures of coagulation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts
Actual Study Start Date : March 19, 2018
Estimated Primary Completion Date : August 3, 2019
Estimated Study Completion Date : October 18, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Experimental: Thrombosomes Biological: Thrombosomes
Freeze-dried platelets

Primary Outcome Measures :
  1. Frequency of adverse events [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Changes in WHO Bleeding Grade [ Time Frame: 6 days ]
  2. Changes in Coagulation Measures [ Time Frame: 2 days ]
    Measures of PT/INR, aPTT, d-dimer, fibrinogen, TAT, PF1+2, TEG, TGA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults up to 74 y/o with any of following: acute leukemia (ALL or AML), myelodysplasia, aplasia, and/or therapy (chemotherapy or radiation) induced bone marrow aplasia or hypoplasia with thrombocytopenia (platelet count ≥ 5,000 and ≤ 70,000/μL) for a minimum of 2 days. May include bone marrow transplant or peripheral or cord blood stem cell recipients, but not subjects with Graft-vs-Host disease.
  • Hospitalized patients (or willing to be hospitalized for 24 hours after Rx) with Modified WHO Grade 1 (subset) or Grade 2 Bleeding Score or at risk for same within 4 weeks of screening. The Grade 1 subset includes patients who have either epistaxis, hematuria, oral petechiae, or bleeding at invasive or other wound sites.
  • No platelet inhibitor drugs within 5 days prior to infusion and during the immediate study 6 Day follow-up period.

Exclusion Criteria:

  • Hx or condition related to thrombosis, embolism or vascular occlusion/ischemia, including but not limited to: TIA, stroke, MI, stent placement, valve replacement and/or repair
  • Currently with an active acute infection, or suspected infection, a single oral temperature of ≥ 101° F or a temperature of ≥ 100.4°F sustained over a 1 h period in past 24 h. Subjects on prophylactic antibiotics are not excluded from study
  • Coagulopathy or receiving anticoagulants that result in PT or aPTT values greater than 1.3 X upper limit of normal or elevated D-dimer of decreased fibrinogen
  • History of any inherited coagulation or platelet function, disorder or ITP, TTP, or HUS
  • Receipt of tranexamic acid or other antifibrinolytics within 48 hrs prior to infusion
  • Rx with an investigational drug w/in 1 month of infusion, other than for treatment of their underlying disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03394755

Layout table for location information
United States, California
City of Hope
Duarte, California, United States, 91010
United States, District of Columbia
Georgetown University Hospital
Washington, District of Columbia, United States, 20016
United States, Illinois
Loyola University Medical Center
Chicago, Illinois, United States, 60130
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03766
United States, Ohio
Hoxworth Blood Center
Cincinnati, Ohio, United States, 45219
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77092
Haukeland University Hospital
Bergen, Norway
Sponsors and Collaborators
Cellphire Therapeutics, Inc.
Department of Health and Human Services
Layout table for investigator information
Study Director: Michael Fitzpatrick Cellphire Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Cellphire Therapeutics, Inc. Identifier: NCT03394755    
Other Study ID Numbers: 2017-1
First Posted: January 9, 2018    Key Record Dates
Last Update Posted: July 11, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cellphire Therapeutics, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases
Anemia, Aplastic
Pathologic Processes
Blood Platelet Disorders
Bone Marrow Failure Disorders
Bone Marrow Diseases